- Home
- JBLU vs AKRO Comparison
JBLU vs AKRO Comparison
Compare JBLU & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JBLU
- AKRO
- Stock Information
- Founded
- JBLU 1998
- AKRO 2017
- Country
- JBLU United States
- AKRO United States
- Employees
- JBLU N/A
- AKRO N/A
- Industry
- JBLU Air Freight/Delivery Services
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- JBLU Consumer Discretionary
- AKRO Health Care
- Exchange
- JBLU Nasdaq
- AKRO Nasdaq
- Market Cap
- JBLU 1.5B
- AKRO 3.9B
- IPO Year
- JBLU N/A
- AKRO 2019
- Fundamental
- Price
- JBLU $4.33
- AKRO $51.76
- Analyst Decision
- JBLU Sell
- AKRO Strong Buy
- Analyst Count
- JBLU 11
- AKRO 6
- Target Price
- JBLU $4.97
- AKRO $82.50
- AVG Volume (30 Days)
- JBLU 18.7M
- AKRO 1.4M
- Earning Date
- JBLU 07-29-2025
- AKRO 08-08-2025
- Dividend Yield
- JBLU N/A
- AKRO N/A
- EPS Growth
- JBLU N/A
- AKRO N/A
- EPS
- JBLU N/A
- AKRO N/A
- Revenue
- JBLU $9,210,000,000.00
- AKRO N/A
- Revenue This Year
- JBLU N/A
- AKRO N/A
- Revenue Next Year
- JBLU $7.84
- AKRO N/A
- P/E Ratio
- JBLU N/A
- AKRO N/A
- Revenue Growth
- JBLU N/A
- AKRO N/A
- 52 Week Low
- JBLU $3.34
- AKRO $21.34
- 52 Week High
- JBLU $8.31
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- JBLU 47.61
- AKRO 49.63
- Support Level
- JBLU $4.30
- AKRO $50.04
- Resistance Level
- JBLU $4.81
- AKRO $53.60
- Average True Range (ATR)
- JBLU 0.20
- AKRO 2.20
- MACD
- JBLU 0.03
- AKRO -0.48
- Stochastic Oscillator
- JBLU 39.29
- AKRO 23.53
About JBLU JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The company has one operating segment, Air Transportation Services, which provides services in the United States, the Caribbean, Latin America, Canada, and Europe. The majority of revenue is generated from the Domestic & Canada segment.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.